AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $260.46, with a market capitalization of 459.43B. The stock trades at a price-to-earnings (P/E) ratio of 73.96 and offers a dividend yield of 2.61%.
On 2026-10-01, AbbVie(ABBV) stock traded between a low of $259.00 and a high of $262.36. Shares are currently priced at $260.46, which is +0.6% above the low and -0.7% below the high.
AbbVie(ABBV) shares are trading with a volume of 3.85M, against a daily average of 4.02M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $269.39 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $269.39 at its peak.
ABBV News
Healthcare investors often face a dilemma when choosing between established giants, but AbbVie (ABBV -0.64%) and Bristol Myers Squibb (BMY -1.51%) present two v...
AbbVie (ABBV) announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ in non-segmental vitiligo, showing continued fa...
AbbVie (ABBV Quick QuoteABBV - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie has completed a Phase 1 study called “A Phase 1 Study to Evaluate the Effect of Itrac...
AbbVie (NYSE:ABBV) reported positive Phase 2 outcomes for zumilokibart in atopic dermatitis at EADV 2026 in Berlin. The firm said zumilokibart has been selecte...
AbbVie (ABBV) announced that detailed results from the multiple ascending dose part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral p...
(RTTNews) - AbbVie (ABBV) reported positive results from the Phase 2 APEX Part B study of zumilokibart, in adults with moderate to severe atopic dermatitis. Al...
When seeking reliable dividend payouts, look no further than the Dividend Kings. Several members of the elite club, including Johnson & Johnson (JNJ Quick Quote...
On CNBC’s “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked UnitedHealth Grou...
AbbVie (ABBV) is investing in its AI infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at w...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.